Abstract
Peptidases can be inhibited by natural or synthetic small-molecule compounds, or by gene-encoded, proteinaceous inhibitors. Small-molecule peptidase inhibitors have been in the spotlight of researchers and pharmaceutical companies for many years. The studies concerning gene-encoded inhibitors are less frequent. The last decade has seen a boom of fungal genomics followed by extensive bioinformatic analyses focused particularly on those species that can cause infections in humans, animals or crops. Many sequences of putative inhibitors have been identified on the basis of homology with gene-encoded peptidase inhibitors of Saccharomyces cerevisiae, mammals or other organisms. However, characterization of the respective proteins is often missing. Gene-encoding peptidase inhibitors are rather diverse in size, mode of action, type of the target peptidase and localization. While some of the inhibitors are secreted to extracellular space and participate in host-pathogen interactions, others act intracellularly and their precise role in fungal physiology is not fully understood. However, most of the gene-encoded peptidase inhibitors are rather selective and efficient, and may be an inspiration for future directions of antimycotic research.
Keywords: AFUEI, Avr2, cystatin, fungi, IA3, IAPs, I2B, inhibitor, pathogen, peptidase, programmed cell death, proteolysis, serpin, TFS1, yeast.
Current Medicinal Chemistry
Title:Fungal Gene-Encoded Peptidase Inhibitors
Volume: 20 Issue: 25
Author(s): V. Bauerova, I. Pichova and O. Hrukova-Heidingsfeldova
Affiliation:
Keywords: AFUEI, Avr2, cystatin, fungi, IA3, IAPs, I2B, inhibitor, pathogen, peptidase, programmed cell death, proteolysis, serpin, TFS1, yeast.
Abstract: Peptidases can be inhibited by natural or synthetic small-molecule compounds, or by gene-encoded, proteinaceous inhibitors. Small-molecule peptidase inhibitors have been in the spotlight of researchers and pharmaceutical companies for many years. The studies concerning gene-encoded inhibitors are less frequent. The last decade has seen a boom of fungal genomics followed by extensive bioinformatic analyses focused particularly on those species that can cause infections in humans, animals or crops. Many sequences of putative inhibitors have been identified on the basis of homology with gene-encoded peptidase inhibitors of Saccharomyces cerevisiae, mammals or other organisms. However, characterization of the respective proteins is often missing. Gene-encoding peptidase inhibitors are rather diverse in size, mode of action, type of the target peptidase and localization. While some of the inhibitors are secreted to extracellular space and participate in host-pathogen interactions, others act intracellularly and their precise role in fungal physiology is not fully understood. However, most of the gene-encoded peptidase inhibitors are rather selective and efficient, and may be an inspiration for future directions of antimycotic research.
Export Options
About this article
Cite this article as:
Bauerova V., Pichova I. and Hrukova-Heidingsfeldova O., Fungal Gene-Encoded Peptidase Inhibitors, Current Medicinal Chemistry 2013; 20 (25) . https://dx.doi.org/10.2174/0929867311320250002
DOI https://dx.doi.org/10.2174/0929867311320250002 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vivo Space Radiation-Induced Non-Targeted Responses: Late Effects on Molecular Signaling in Mitochondria
Current Molecular Pharmacology The Use of TNF Family Ligands and Receptors and Agents which Modify their Interaction as Therapeutic Agents
Current Drug Targets β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets Peptides in Melanoma Therapy
Current Pharmaceutical Design Editorial [Hot Topic: Nutraceuticals and Prevention of Neurodegeneration (Executive Guest Editors: Thea Magrone and Emilio Jirillo)]
Current Pharmaceutical Design Novel N-mustard-benzimidazoles/benzothiazoles Hybrids, Synthesis and Anticancer Evaluation
Anti-Cancer Agents in Medicinal Chemistry The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship
Current Medicinal Chemistry Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia
Current Cancer Drug Targets Evaluation of the Radioprotective Potential of the Polyphenol Norbadione A
Letters in Drug Design & Discovery Aminopeptidases of Malaria Parasites: New Targets for Chemotherapy
Infectious Disorders - Drug Targets The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry Differential Interactions of Cytochrome P450 3A5 and 3A4 with Chemotherapeutic Agent-Vincristine: A Comparative Molecular Dynamics Study
Anti-Cancer Agents in Medicinal Chemistry Haploinsufficiency of DNA Damage Response Genes and their Potential Influence in Human Genomic Disorders
Current Genomics Metastatic Cancer Stem Cells: New Molecular Targets for Cancer Therapy
Current Pharmaceutical Biotechnology The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters Immunological Aspects of Adult T-Cell Leukemia/Lymphoma (ATLL), a Possible Neoplasm of Regulatory T-Cells
Current Immunology Reviews (Discontinued) Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Current Topics in Medicinal Chemistry Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets